초록

Tissue patches and associated systems and methods are described. Certain embodiments are related to inventive systems and methods in which tissue patches can be made quickly and robustly without the use of complicated fabrication or sterilization equipment.

대표청구항 ▼

1. A patch, comprising: a primer region comprising a water-activated polymeric adhesive; andan unsupported solid matrix comprising fibrin positioned over at least a portion of the primer region, wherein: the unsupported solid matrix has a Young's modulus of about 10 GPa or less after sterilization u

1. A patch, comprising: a primer region comprising a water-activated polymeric adhesive; andan unsupported solid matrix comprising fibrin positioned over at least a portion of the primer region, wherein: the unsupported solid matrix has a Young's modulus of about 10 GPa or less after sterilization using gamma radiation at an intensity of 30 kGy, andthe patch is configured for application to a tissue surface. 2. A patch, comprising: a primer region comprising a water-activated polymeric adhesive; andan unsupported solid matrix comprising fibrin positioned over at least a portion of the primer region, wherein: the fibrin within the unsupported solid matrix is cross-linked to a degree such that, after submerging the unsupported solid matrix in a 6M aqueous solution of urea at 25° C., the unsupported solid matrix retains its structural integrity over a period of at least about 2 hours, andthe patch is configured for application to a tissue surface. 3. The patch of claim 1, wherein the water-activated polymeric adhesive comprises a co-polymer of a vinyl ether and maleic anhydride. 4. The patch of claim 3, wherein the vinyl ether comprises an alkyl vinyl ether. 5. The patch of claim 4, wherein the alkyl group in the alkyl vinyl ether comprises from 1 to 18 carbons. 6. The patch of claim 4, wherein the alkyl vinyl ether comprises methylvinyl ether. 7. The patch of claim 3, wherein the vinyl ether comprises a divinyl ether. 8. The patch of claim 1, wherein the matrix optionally comprises fibrinogen, and wherein the total of fibrin and fibrinogen within the matrix is at least about 10 grams per liter of the matrix. 9. The patch of claim 1, wherein the matrix optionally comprises fibrinogen, and wherein the total of fibrin and fibrinogen within the matrix is between about 10 grams per liter and about 150 grams per liter of the matrix. 10. The patch of claim 1, wherein a concentration of the fibrin within the matrix is at least about 10 grams per liter of the matrix. 11. The patch of claim 1, wherein the patch comprises thrombin within the primer region. 12. The patch of claim 1, wherein the water-activated polymeric adhesive is present within the primer region in an amount of from about 5 wt % to about 50 wt %. 13. The patch of claim 1, wherein the matrix optionally comprises fibrinogen, and wherein the weight ratio of fibrin to fibrinogen within the matrix is at least about 5:1. 14. The patch of claim 1, wherein the water-activated polymeric adhesive comprises one or more polymers of acrylic acid. 15. The patch of claim 14, wherein the one or more polymers of acrylic acid are cross-linked with a polyalkenyl ether and/or a divinyl alcohol. 16. The patch of claim 15, wherein the one or more polymers of acrylic acid are cross-linked with a polyalkenyl ether. 17. The patch of claim 15, wherein the one or more polymers of acrylic acid are cross-linked with a divinyl alcohol. 18. The patch of claim 1, wherein the unsupported solid matrix has an aspect ratio of at least about 5:1. 19. The patch of claim 1, wherein the unsupported solid matrix has an average thickness of between about 500 microns and about 1 cm. 20. The patch of claim 1, wherein the unsupported solid matrix has at least one cross-sectional dimension of at least about 1 cm. 21. The patch of claim 1, wherein the patch is sterile. 22. The patch of claim 2, wherein the water-activated polymeric adhesive comprises a co-polymer of a vinyl ether and maleic anhydride. 23. The patch of claim 22, wherein the vinyl ether comprises an alkyl vinyl ether. 24. The patch of claim 23, wherein the alkyl group in the alkyl vinyl ether comprises from 1 to 18 carbons. 25. The patch of claim 23, wherein the alkyl vinyl ether comprises methylvinyl ether. 26. The patch of claim 22, wherein the vinyl ether comprises a divinyl ether. 27. The patch of claim 2, wherein the matrix optionally comprises fibrinogen, and wherein the total of fibrin and fibrinogen within the matrix is at least about 10 grams per liter of the matrix. 28. The patch of claim 2, wherein the matrix optionally comprises fibrinogen, and wherein the total of fibrin and fibrinogen within the matrix is between about 10 grams per liter and about 150 grams per liter of the matrix. 29. The patch of claim 2, wherein the concentration of fibrin within the matrix is at least about 10 grams per liter of the matrix. 30. The patch of claim 2, wherein the patch comprises thrombin within the primer region. 31. The patch of claim 2, wherein the water-activated polymeric adhesive is present within the primer region in an amount of from about 5 wt % to about 50 wt %. 32. The patch of claim 2, wherein the matrix optionally comprises fibrinogen, and wherein the weight ratio of fibrin to fibrinogen within the matrix is at least about 5:1. 33. The patch of claim 2, wherein the water-activated polymeric adhesive comprises one or more polymers of acrylic acid. 34. The patch of claim 33, wherein the one or more polymers of acrylic acid are cross-linked with a polyalkenyl ether and/or a divinyl alcohol. 35. The patch of claim 34, wherein the one or more polymers of acrylic acid are cross-linked with a polyalkenyl ether. 36. The patch of claim 34, wherein the one or more polymers of acrylic acid are cross-linked with a divinyl alcohol. 37. The patch of claim 2, wherein the unsupported solid matrix has an aspect ratio of at least about 5:1. 38. The patch of claim 2, wherein the unsupported solid matrix has an average thickness of between about 500 microns and about 1 cm. 39. The patch of claim 2, wherein the unsupported solid matrix has at least one cross-sectional dimension of at least about 1 cm. 40. The patch of claim 2, wherein the patch is sterile. 41. The patch of claim 2, wherein the fibrin within the unsupported solid matrix is cross-linked to a degree such that, after submerging the unsupported solid matrix in an 8M aqueous solution of urea at 25° C., the unsupported solid matrix retains its structural integrity over a period of at least about 2 hours.